The PennZone

  • Home
  • Non-profit
  • Technology
  • Education
  • Business
  • Construction
  • Entertainment
  • Event
  • Marketing

Dr. Jeff Gelblum Provides Alzheimer's Treatment to Patients in the US and Abroad
The PennZone/10277342

Trending...
  • Creative Investment Research Analysis Finds Slower GDP Growth, Rising Inflation
  • Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
  • UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
Alzheimer's Treatment
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.

The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.

Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.

He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."

More on The PennZone
  • A Foundational Claim in Human Secrecy Goes Public
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Fourth Annual Free Training Day Mid-Atlantic Returns Sept. 19, 2026
  • Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana
  • Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026

Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.

Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy.  This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."

For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.

His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.

Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.

More on The PennZone
  • Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
  • Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
  • Colonial Nissan Enhances Ownership Experience with Hall of Fame Package
  • From Broken to Soaring Week 40
  • Costa Oil Takes the Spotlight as Primary Sponsor at Pocono, Celebrates Team with Employee Appreciation Day Costa Oil to back the

Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."

He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.

About Jeffrey Gelblum, MD, FAAN

Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/

Contact
First Choice Neurology
***@fcneurology.net


Source: First Choice Neurology

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • CAPHRA warns push for ASEAN vape ban ignores science
  • Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
  • ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
  • P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
  • Cabinetworks Group announces recipient of 2025 Plant of the Year
  • Honesdale Painters Launch Season With Act of Community Kindness
  • Tuckwell Machinery Launches New Range of Woodworking Machinery
  • A Brave Little Hero with Four Paws
  • Pittsburgh-Area Author Erica L. Day Releases HER, a Christian Second-Chance Romance and Its Own Comp
  • Revenue Optics Expands Its Private Equity Practice as Sponsors Move Inside Sales to the Center of Distribution Value Creation
  • Ecuador Freedom Launches First Scheduled Motorcycle Tour of Northern Peru's Lost Kingdoms
  • Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak
  • Neuro Recovery Institute Showcases Emerging Immersive Neuro-Rehabilitation Technology at Clinical Innovation Open House
  • Community, Conservation & Waterwise Inspiration Bloom on June 6
  • Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
  • Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
  • CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
  • Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup
  • Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
  • Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health

Popular on PennZone

  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities
  • Veikkaus Appoints New CFO as Finland's Gambling Monopoly Braces for Breakup
  • Philadelphia's First Ginger Store Honored With City Citation for Nine Years of Health and Wellness
  • ICTPBX Released: White-Label, Multi-Tenant Open Source PBX Platform for ITSPs
  • All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
  • RAATV Premieres Original Reality Series "The Access Index: Jackson" June, 19

Similar on PennZone

  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • From Broken to Soaring Week 40
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • CAPHRA warns push for ASEAN vape ban ignores science
  • Lineus Medical Completes Financial Restructuring with KMF Investments- Launching a New Era for SafeBreak
  • Neuro Recovery Institute Showcases Emerging Immersive Neuro-Rehabilitation Technology at Clinical Innovation Open House
  • Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
  • CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
  • Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us